Search Results - "Kutner, Mark E"
-
1
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Published in The Lancet (British edition) (17-11-2018)“…LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for…”
Get full text
Journal Article -
2
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Published in The Lancet (British edition) (13-11-2021)“…We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus…”
Get full text
Journal Article -
3
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial
Published in JAMA network open (01-10-2021)“…There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk of infection. To demonstrate manufacturing…”
Get full text
Journal Article